Francesca Colavita
A5002809468- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral Infections and Vectors
- SARS-CoV-2 detection and testing
- Viral Infections and Outbreaks Research
- Bacillus and Francisella bacterial research
- Poxvirus research and outbreaks
- Mosquito-borne diseases and control
- Herpesvirus Infections and Treatments
- Long-Term Effects of COVID-19
- Viral gastroenteritis research and epidemiology
- Biosensors and Analytical Detection
- Animal Virus Infections Studies
- Virus-based gene therapy research
- Respiratory viral infections research
- Malaria Research and Control
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Hepatitis B Virus Studies
- Disaster Response and Management
- Virology and Viral Diseases
- Vaccine Coverage and Hesitancy
- COVID-19 Impact on Reproduction
- Viral-associated cancers and disorders
- Advanced biosensing and bioanalysis techniques
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
1961-2025
University of Rome Tor Vergata
2023-2024
University of Siena
2022
Ospedale Sacro Cuore Don Calabria
2022
State Key Laboratory of Virology
2021
Translational Research Institute
2021
Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes
2021
Office of Infectious Diseases
2021
Center for Prevention and Treatment of Infections
2016-2019
Analysis of 179 new Ebola virus sequences from patient samples collected in Guinea between March 2014 and January 2015 shows how different lineages evolved spread West Africa. Miles Carroll colleagues report describe the genetic evolution circulating Africa, based on 2015. Their analysis Africa Sierra Leone, Liberia. is currently witnessing most extensive (EBOV) outbreak so far recorded1,2,3. Until now, there have been 27,013 reported cases 11,134 deaths. The origin thought to a zoonotic...
IntroductionSeveral recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar those seen previously in SARS-CoV and MERS-CoV infected patients.ObjectiveWe present some remarkable the first two patients identified Italy with COVID-19 infection travelling from Wuhan, China. The follow-up X-Rays CT scans was also included, showing a progressive adult respiratory distress syndrome...
Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate according current CD4 T-cell count.
The pathogenesis of SARS-CoV-2 remains to be completely understood, and detailed cellular cytopathic effects requires definition. We performed a comparative ultrastructural study SARS-CoV-1 infection in Vero E6 cells lungs from deceased COVID-19 patients. induces rapid death associated with profound changes cells. Type II pneumocytes lung tissue showed prominent altered features numerous vacuoles swollen mitochondria presence abundant lipid droplets. accumulation lipids was the most striking...
Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a consequence of waning immunity. Serum antibodies represent the most measurable outcome vaccine-induced B cell memory. When decline, memory cells expected to persist and perform their function, preventing clinical disease. We investigated whether BNT162b2 mRNA vaccine induces durable functional vivo against 3, 6, 9 months after second dose cohort health care workers (HCWs). While we observed physiological...
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay IFN-γ production 216 PLWH on ART advanced disease (CD4 count <200 cell/mm
Abstract Background Remdesivir is a prodrug of the nucleoside analogue GS-441524 and under evaluation for treatment SARS-CoV-2-infected patients. Objectives To evaluate pharmacokinetics remdesivir in plasma, bronchoalveolar aspirate (BAS) CSF two critically ill COVID-19 Methods was administered at 200 mg loading dose on first day followed by 12 days 100 Blood samples were collected immediately after (C0) 1 (C1) 24 h (C24) intravenous administration 3 until 9. BAS Days 4, 7 9 from both...
Data concerning the transmission of novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) in paucisymptomatic patients are lacking. We report an Italian case disease 2019 with multiple biological samples positive for SARS-CoV-2. This was detected using World Health Organization protocol on cases and contact investigation. Current discharge criteria impact extra-pulmonary SARS-CoV-2 discussed.
SARS-CoV-2 serum neutralization assay represents the gold standard for assessing antibody-mediated protection in naturally infected and vaccinated individuals. In present study, 662 samples collected from February 2020 to January 2021 acute convalescent COVID-19 patients were tested determine neutralizing antibody (NAb) titers using a microneutralization test (MNT) live SARS-CoV-2. Moreover, anti-SARS-CoV-2 IgG, IgA, IgM directed against different viral antigens measured by high-throughput...
Vaccination is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, a massive worldwide scientific effort resulted in rapid development of effective vaccines. This work aimed define dynamics humoral cell-mediated immune response cohort care workers (HCWs) who received two-dose BNT162b2-mRNA vaccination. The serological was evaluated by quantifying anti-RBD neutralizing antibodies. performed whole blood test Th1 cytokines (IFN-γ, TNF-α, IL-2), produced spike...
Abstract Objectives Simple and standardized methods to establish correlates vaccine-elicited SARS-CoV-2 protection are needed. Methods An observational study on antibody response a mRNA vaccine (Comirnaty) was performed health care workers (V, n=120). Recovered COVID-19 patients (N, n=94) were used for comparison. Antibody evaluated by quantitative anti-receptor binding domain IgG (anti-RBD) commercial assay virus microneutralization test (MNT), in order threshold of anti-RBD units (BAU)...
Objective To assess the kinetics of humoral and cell-mediated responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in rheumatoid arthritis (RA) patients treated with different immunosuppressive therapies. Methods Following vaccine completed schedule, health care workers (HCWs, n = 49) RA (n 35) were enrolled at 5 weeks (T1) 6 months (T6) first dose BNT162b2-mRNA vaccination. Serological response was assessed by quantifying anti-receptor-binding domain...
We report the follow-up laboratory investigation of three MPXV cases infected in May-June 2022 from diagnosis to disease resolution, monitoring viral shedding different body fluids and antibody kinetics. Out 138 non-lesion samples, DNA was found 92.3% saliva, 85.7% semen, 86.2% oropharyngeal swabs, 51.7% plasma, 46.1% stool, 9.5% urine samples. Viral load quantified by digital PCR widely varied, but tend be higher stool. Replication competent virus recovered four out seventeen including 1...
Little evidence on coronavirus disease 2019 (COVID-19) in people living with HIV (PLWH) is currently available. We reported clinical and viroimmunological data of all HIV-positive patients admitted to our center COVID-19 from March 1 May 12, 2020. Overall, five were included: virologically-suppressed antiretroviral therapy CD4+ count was greater than 350 cell/mm3 but two patients. Although had pneumonia admission, only one developed respiratory failure. Severe acute syndrome 2 (SARS-CoV-2)...
Abstract The current epidemic of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for the development inhibitors viral replication. Here, we performed a bioinformatic analysis published and purported SARS-CoV-2 antivirals including imatinib mesylate that found to suppress replication on Vero E6 cells that, according literature other coronaviruses is likely act on-target, as tyrosine kinase inhibitor. We identified cluster with...